Dominant negative p63 isoform expression in head and neck squamous cell carcinoma

Laryngoscope

Volumn 114, Issue 12, 2004, Pages 2063-2072

  Sniezek, Joseph C ^a   Matheny, Keith E ^b   Westfall, Mathew D ^b   Pietenpol, Jennifer A ^b  

^a TRIPLER ARMY MEDICAL CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Immunohistochemistry; p53; p63; Reverse transcriptase polymerase chain reaction; Squamous cell carcinoma

Indexed keywords

PROTEIN P63; PROTEIN SUBUNIT; RNA;

ARTICLE; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LICHEN PLANUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SYMPTOM; TISSUE DISTRIBUTION; WESTERN BLOTTING;

BASE SEQUENCE; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEIN ISOFORMS; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SAMPLING STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10044266819     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000149437.35855.4b     Document Type: Article

References (45)

1. Gleich LL. Gene therapy for head and neck cancer. Laryngoscope 2000;110:708-726.
2. Califano J, van der Riet P, Westra W, et al. Genetic progressive model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488.
3. Schoelch ML, Regazi JA, Dekker NP. Cell cycle proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999;35:333-342.
4. Kropveld A, Rozemuller EH, Leppers FGJ. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers. Lab Invest 1999;79:347-353.
5. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:808-819.
6. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homologue at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316.
7. Yang A, McKeon F. p63 and p73: p53 mimics, menaces, and more. Nat Rev Mol Cell Biol 2000;1:199-207.
8. Kaelin WG, Jr. The p53 gene family. Oncogene 1999;18:7701-7705.
9. Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JYJ. Structure, function and regulation of p63 and p73. Cell Death Differ 1999;6:1146-1153.
10. Arrowsmith CH. Structure and function in the p53 family. Cell Death Differ 1999;6:1169-1173.
11. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63α and deltaNp63α in benign and malignant oral epithelial lesions. Int J Cancer 2000;87:368-372.
12. Stewart ZA, Pietenpol JA. p53 signaling and cell cycle checkpoints. Chem Res Toxicol 2001;14:243-263.
13. Sidransky D. Molecular biology of head and neck tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997:735.
14. Hall PA, Campbell SJ, O'Neill DJ, Nylander K, Carey FA, Kernohan NM. Expression of the p53 homologue p63a and deltaNp63a in normal and neoplastic cells. Carcinogenesis 2000;21:153-160.
15. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999;398:714-718.
16. Mills AA, Zheng BH, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999;398:708-713.
17. Hibi K, Trink B, Patturajan M, Westra WH, Hill DE, Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proceedings of the National Academy of Sciences 2000;97:5462-5467.
18. Liefer K, Koster M, Wang X, Yang A, McKeon F, Roop D. Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000;60:4016-4020.
19. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000;19:3439-3444.
20. Dekker NP, Lozada-Nur F, Lagenaur LA, MacPhail LA, Bloom CY, Regezi JA. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1997;26:170-175.
21. Majorana A, Facchetti F, Pellegrini W, Sapelli P. Apoptosis-associated markers in oral lichen planus. J Oral Pathol Med 1999;28:47-48.
22. 2 checkpoint is retinoblastoma protein dependent. Mol Cell Biol 2000;20:4210-4223.
23. Szak ST, Mays DJ, Pietenpol JA. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 2001;21:3375-3386.
24. Yamaguchi K, Wu L, Caballero O, et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer 2000;86:684-689.
25. Sniezek JC, Matheny KE, Burkey BB, Netterville JL, Pietenpol JA. Expression of p63 and 14-3-3σ in normal and hyper-differentiated mucosa of the upper aerodigestive tract. Otolaryngol Head Neck Surg 2002;126:598-601.
26. Clayman GL. The current status of gene therapy. Semin Oncol 2000;27(Suppl 8):39-43.
27. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-1455.
28. Cordon-Cardo C. Mutation and cell cycle regulators. Am J Pathol 1995;147:545-560.
29. Clayman GL, El-Naggar AK, Lippman SM, et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:2221-2232.
30. Clayman GL, El-Naggar AK, Rith JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
31. Clayman GL. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999;5:1715-1722.
32. Pirollo KF, Hao Z, Rait A, et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997;14:1735-1741.
33. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079-1086.
34. National Cancer Institute: Phase II study of Ad5CMV-53 for recurrent squamous cell carcinoma of the head and neck. PDQ clinical trial abstract, National Institutes of Health. Available on the web at: http://cancernet.nci. nih.gov/cgibin/cancer-patshow?file=pro13321.html. Accessed August 2003.
35. Ahomadegbe J. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases: absence of correlation with clinical outcome - frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-1227.
36. Boyle J. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-4480.
37. Yang A. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature 2000;404:99-103.
38. Parsa R, Yang A, McKeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999;113:1099-1105.
39. Celli J. Heterozygous germline mutations in the p53 homologue p63 are the cause of EEC syndrome. Cell 1999;99:143-153.
40. Weinberg WC, Azzoli CG, Chapman K, Levine AJ, Yuspa SH. p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. Oncogene 1995;10:2271-2279.
41. Hesselmeyer K. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 1996;93:479-484.
42. Kaelin WG. The emerging p53 gene family. J Natl Cancer Inst 1999;91:594-598.
43. Pellegrini G, Dellambra E, Golisano O, et al. p63 identifies keratinocyte stem cells. Proceedings of the National Academy of Sciences 2001;98:3156-3161.
44. Matheny KE, Barbieri CE, Sniezek JC, Arteaga CL, Pietenpol JA. Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. Laryngoscope 2003;113:936-939.
45. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The ΔNp63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol Cell Biol 2003;23:2264-2276.